All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

USC Norris Comprehensive Cancer Center Opens State-of-the-Art Newport Beach Radiation Oncology and Imaging Center

April 17th 2025

USC Norris Comprehensive Cancer Center has opened Keck Medicine of USC – Newport Beach Radiation Oncology and Imaging, a radiation oncology center.

Belantamab Mafodotin–Based Combos Win UK Approval for R/R Myeloma

April 17th 2025

Two belantamab mafodotin–based combinations have been approved in the United Kingdom for relapsed/refractory multiple myeloma.

Bria-IMT Plus Checkpoint Inhibition Yields Potential OS Benefit in Pretreated HR+ Breast Cancer

April 17th 2025

Bria-IMT plus retifanlimab generated a potential overall survival benefit in heavily pretreated, metastatic hormone receptor–positive breast cancer.

Companion Diagnostic Nets European IVDR Certification for Pembrolizumab Eligibility in Gastric/GEJ Adenocarcinoma

April 17th 2025

The PD-L1 IHC 22C3 pharmDx assay has been granted European IVDR certification for identifying pembrolizumab eligibility in gastric/GEJ adenocarcinoma.

Dasatinib Plus CAR T-Cell Therapy Shows Efficacy in Ph+ Acute Lymphoblastic Leukemia

April 17th 2025

Dasatinib plus CAR T cells led to high CMR and LFS rates with a good safety profile in Ph-positive acute lymphoblastic leukemia.

Talazoparib/Enzalutamide Combo, Radioligand Therapy Expand Options in mCRPC

April 17th 2025

Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for advanced metastatic prostate cancer.

Responses With Compassionate Use of MDC-CAR-BCMA001 Support Further Study in R/R Myeloma and AL Amyloidosis

April 17th 2025

Kiavasch Mohammad Nejad Farid, MD, discusses the signs of activity and safety with MDC-CAR-BCMA001 in pretreated patients with AL amyloidosis and myeloma.

Anthracycline-Sparing Strategies Help Refine HER2+ Breast Cancer Management

April 17th 2025

Paolo Tarantino, MD, discusses the growing emphasis on anthracycline-sparing approaches for the treatment of HER2-positive breast cancer.

MRD-Guided Zanubrutinib/Venetoclax/Obinutuzumab Triplet Induces Deep Remissions in R/R CLL

April 16th 2025

Zanubrutinib plus venetoclax and obinutuzumab was well tolerated—aside from COVID-19–related toxicities—in patients with relapsed/refractory CLL.

Targeted Therapies Both Refine and Raise Questions About CRPC Treatment Decision-Making

April 16th 2025

Evan Y. Yu, MD, discusses PARP inhibitor treatment selection and sequencing for patients with metastatic castration-resistant prostate cancer.

Encorafenib/Cetuximab Plus mFOLFOX6 Provides New SOC for BRAF V600E+ mCRC

April 16th 2025

Scott Kopetz, MD, PhD, FACP, highlights the efficacy of encorafenib/cetuximab with mFOLFOX6 in BRAF V600E–mutated metastatic colorectal cancer.

Molecular Profiling, Endocrine Sensitivity Are Key to Managing Later-Line HR+/HER2-Negative Breast Cancer

April 16th 2025

Erika P. Hamilton, MD, discusses the current role of CDK4/6 inhibitors and evolving targeted therapies in advanced HR-positive, HER2-negative breast cancer.

Dana-Farber Researchers Receive AACR 2025 Scientific Achievement Awards

April 16th 2025

Three researchers from Dana-Farber Cancer Institute have been selected by the American Association for Cancer Research (AACR) as recipients of 2025 Scientific Achievement Awards.

TLX101 Has Preliminary Safety and Clinical Activity in Recurrent High-Grade Glioma

April 16th 2025

TLX101 was associated with a favorable safety profile and preliminary signs of clinical activity in patients with recurrent high-grade glioma.

NDA Accepted in China for Zurletrectinib for NTRK Gene Fusion+ Advanced Solid Tumors

April 16th 2025

A new drug application for zurletrectinib has been accepted in China for the treatment of patients with NTRK gene fusion–positive advanced solid tumors.

RCC Treatment Decision-Making Requires a Balance of Efficacy and Individual Patient Considerations

April 16th 2025

Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for renal cell carcinoma.

Pembrolizumab-Based Regimens Gain Ground in TNBC Management

April 16th 2025

Nerea Lopetegui-Lia, MD, discusses the prevalence of and risk factors for triple-negative breast cancer, and strategies that may improve survival outcomes.

CCTG BR.31 Data Show Adjuvant Durvalumab Does Not Alter Relapse Frequency or Patterns in Resected NSCLC

April 16th 2025

Adjuvant durvalumab was not associated with a reduction in the frequency of relapse in NSCLC.

FDA-Approved Isotope Therapies Provide 2 Options in the Castration-Resistant Prostate Cancer Armamentarium

April 15th 2025

Yung Lyou, MD, discusses FDA-approved isotope therapies and the development of novel therapies in the castration-resistant prostate cancer space.

Nivolumab-Based, Response-Adapted Approach Yields Durable Responses in Frontline Follicular Lymphoma

April 15th 2025

Response-adapted treatment with nivolumab with or without rituximab produced responses in treatment-naive follicular lymphoma.